Research programme: tumour suppressor gene pathway inhibitors - Bristol-Myers Squibb/Exelixis
Latest Information Update: 12 Feb 2010
At a glance
- Originator Bristol-Myers Squibb; Exelixis
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Jan 2006 This programme is still in active development
- 04 Oct 2001 Preclinical development for Cancer in USA (Unknown route)